Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Date
2020Author
Tostanoski, Lisa H.
Wegmann, Frank
Martinot, Amanda J.
Loos, Carolin
McMahan, Katherine
Mercado, Noe B.
Yu, Jingyou
Chan, Chi N.
Bondoc, Stephen
Starke, Carly E.
Nekorchuk, Michael
Busman-Sahay, Kathleen
Piedra-Mora, Cesar
Wrijil, Linda M.
Ducat, Sarah
Custers, Jerome
Atyeo, Caroline
Fischinger, Stephanie
Burke, John S.
Feldman, Jared
Hauser, Blake M.
Caradonna, Timothy M.
Bondzie, Esther A.
Dagotto, Gabriel
Jacob-Dolan, Catherine
Lin, Zijin
Mahrokhian, Shant H.
Nampanya, Felix
Nityanandam, Ramya
Pessaint, Laurent
Porto, Maciel
Ali, Vaneesha
Benetiene, Dalia
Tevi, Komlan
Andersen, Hanne
Lewis, Mark G.
Schmidt, Aaron G.
Lauffenburger, Douglas A.
Alter, Galit
Estes, Jacob D.
Schuitemaker, Hanneke
Zahn, Roland
Barouch , Dan H.
Metadata
Show full item record
Documentos PDF
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a
clinically mild illness, but some individuals develop severe
pneumonia, respiratory failure and death1–4. Studies of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in hamsters5–7
and nonhuman primates8–10 have
generally reported mild clinical disease, and preclinical
SARS-CoV-2 vaccine studies have demonstrated reduction of
viral replication in the upper and lower respiratory tracts in
nonhuman primates11–13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical
disease, including high levels of virus replication in tissues,
extensive pneumonia, weight loss and mortality in a subset of
animals. A single immunization with an adenovirus serotype
26 vector-based vaccine expressing a stabilized SARS-CoV-2
spike protein elicited binding and neutralizing antibody
responses and protected against SARS-CoV-2-induced
weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of
SARS-CoV-2 vaccines, therapeutics and pathogenesis.
Palabras clave
Ad26 vaccine; SARS-CoV-2; Clinical diseaseLink to resource
https://doi.org/10.1038/s41591-020-1070-6Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.